• Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
• Previous divisional structure is now replaced with three newly formed CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
• The model comes into effect today, and is reflected on the updated Lonza.com website

Commentary:
Lonza’s shift to a simplified operating model marks a pivotal step in its transformation journey. By aligning around three focused CDMO platforms and eliminating layers, the company is clearly doubling down on agility, customer-centricity, and execution excellence. This bold move not only reinforces its One Lonza vision but also sets the stage for scalable growth and sharper strategic focus across its multimodal offerings

Lonza has announced that its new simplified and streamlined operating model is effective from 1 April 2025.. At its Investor Update in December 2024, Lonza announced its new One Lonza vision and strategy, centered around the Lonza Engine, which brings together the company’s unique core competencies that enable outstanding value creation.

The Lonza Engine comprises five key components including: high performance teams; a strong scientific, technological and digital ecosystem; unparalleled customer partnerships; end-to-end execution excellence; and plug-and-play investment and integration capabilities. The simplified One Lonza organization has been designed to enhance customer experience, provide scalability for future growth and strengthen Lonza’s multimodality offering.

 Lonza’s offering comprises three newly-formed CDMO Business Platforms:

• Integrated Biologics, led by Gordon Bates, advances Lonza’s best-in-class integrated offering and comprises Mammalian and Drug Product Services.
• Advanced Synthesis, led by Christian Seufert, combines leading hybrid chemistry and biology solutions and comprises the former Small Molecules division and Bioconjugates.
• Specialized Modalities, led by Daniel Palmacci, pioneers and scales cutting-edge technologies including Cell & Gene Technologies, mRNA, Microbial, and Bioscience. 

Within the new structure, the business unit layer has been removed, and the three business platforms now each directly manage multiple technology platforms. The Capsules & Health Ingredients (CHI) business will continue to operate in its existing structure.

The new organizational structure will further enable Lonza to capture growth opportunities by empowering key Group Functions and improving execution capabilities, including a unified go-to-market approach and an increased focus on excellence in asset construction and operation.

Continuing to operate in its current structure, the CHI business is now led by Jean-Christophe Hyvert. Lonza plans to part ways with the business at the appropriate time and in the best interests of shareholders and stakeholders, while ensuring CHI continues to serve its customers and deliver profitable growth as the global market leader in its space.

Lonza will publish its restated financials for 2024 in June to provide investors with comparable figures for the Half-Year 2025 reporting on 23 July 2025. On 9 May 2025, Lonza will publish its qualitative Q1 2025 update in the former reporting structure.